These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
89 related articles for article (PubMed ID: 26619770)
1. Adjunctive Ziprasidone in Major Depression and the Current Status of Adjunctive Atypical Antipsychotics. Nelson JC Am J Psychiatry; 2015 Dec; 172(12):1176-8. PubMed ID: 26619770 [No Abstract] [Full Text] [Related]
3. Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Efficacy Results From a Randomized, Double-Blind, Placebo-Controlled Study. Papakostas GI; Fava M; Baer L; Swee MB; Jaeger A; Bobo WV; Shelton RC Am J Psychiatry; 2015 Dec; 172(12):1251-8. PubMed ID: 26085041 [TBL] [Abstract][Full Text] [Related]
4. Augmentation of antidepressants with atypical antipsychotics: a review of the current literature. Philip NS; Carpenter LL; Tyrka AR; Price LH J Psychiatr Pract; 2008 Jan; 14(1):34-44. PubMed ID: 18212601 [TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. Marcus RN; McQuade RD; Carson WH; Hennicken D; Fava M; Simon JS; Trivedi MH; Thase ME; Berman RM J Clin Psychopharmacol; 2008 Apr; 28(2):156-65. PubMed ID: 18344725 [TBL] [Abstract][Full Text] [Related]
6. Use of atypical antipsychotics in mood disorders. Weizman R; Weizman A Curr Opin Investig Drugs; 2001 Jul; 2(7):940-5. PubMed ID: 11757795 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial. Sachs GS; Ice KS; Chappell PB; Schwartz JH; Gurtovaya O; Vanderburg DG; Kasuba B J Clin Psychiatry; 2011 Oct; 72(10):1413-22. PubMed ID: 21672493 [TBL] [Abstract][Full Text] [Related]
8. Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features. Trivedi MH; Thase ME; Fava M; Nelson CJ; Yang H; Qi Y; Tran QV; Pikalov A; Carlson BX; Marcus RN; Berman RM J Clin Psychiatry; 2008 Dec; 69(12):1928-36. PubMed ID: 19192475 [TBL] [Abstract][Full Text] [Related]
9. Aripiprazole as an adjunctive treatment for refractory major depression. Hellerstein DJ Prog Neuropsychopharmacol Biol Psychiatry; 2004 Dec; 28(8):1347-8. PubMed ID: 15588762 [No Abstract] [Full Text] [Related]
10. Efficacy of ziprasidone monotherapy in patients with anxious depression: a 12-week, randomized, double-blind, placebo-controlled, sequential-parallel comparison trial. Heo JY; Jeon HJ; Fava M; Mischoulon D; Baer L; Clain A; Doorley J; Pisoni A; Papakostas GI J Psychiatr Res; 2015 Mar; 62():56-61. PubMed ID: 25659187 [TBL] [Abstract][Full Text] [Related]
11. Ziprasidone induction of hypomania in depression? Davis R; Risch SC Am J Psychiatry; 2002 Apr; 159(4):673-4. PubMed ID: 11925314 [No Abstract] [Full Text] [Related]
12. Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study. Lin CH; Lin SH; Jang FL J Clin Psychopharmacol; 2011 Oct; 31(5):563-8. PubMed ID: 21869699 [TBL] [Abstract][Full Text] [Related]
13. Intranasal oxytocin as an adjunct to escitalopram in major depression. Scantamburlo G; Ansseau M; Geenen V; Legros JJ J Neuropsychiatry Clin Neurosci; 2011; 23(2):E5. PubMed ID: 21677229 [No Abstract] [Full Text] [Related]
14. Unclear clinical significance of findings in adjunctive aripiprazole for major depressive disorder: comments on article by Marcus et al. Tsai AC J Clin Psychopharmacol; 2009 Feb; 29(1):91-2; author reply 92-3. PubMed ID: 19142118 [No Abstract] [Full Text] [Related]
15. Aripiprazole adjunctive to antidepressant therapy. Marcus RM; Sanchez R; Frost M; McQuade RD Am J Psychiatry; 2011 Feb; 168(2):211; author reply 211. PubMed ID: 21297051 [No Abstract] [Full Text] [Related]
16. Ziprasidone-induced galactorrhea: a case report. Kopecek M; Bares M; Mohr P Neuro Endocrinol Lett; 2005 Feb; 26(1):69-70. PubMed ID: 15726024 [TBL] [Abstract][Full Text] [Related]
17. Palmitoylethanolamide as adjunctive therapy in major depressive disorder: A double-blind, randomized and placebo-controlled trial. Ghazizadeh-Hashemi M; Ghajar A; Shalbafan MR; Ghazizadeh-Hashemi F; Afarideh M; Malekpour F; Ghaleiha A; Ardebili ME; Akhondzadeh S J Affect Disord; 2018 May; 232():127-133. PubMed ID: 29486338 [TBL] [Abstract][Full Text] [Related]
18. The use of adjunctive antipsychotics to treat depression in UK primary care. Lamy FX; Saragoussi D; Johnson ME; Guiraud-Diawara A; Jørgensen KT; Loze JY; Maguire A Curr Med Res Opin; 2017 May; 33(5):891-898. PubMed ID: 28277876 [TBL] [Abstract][Full Text] [Related]
19. Global benefit-risk analysis of adjunctive aripiprazole in the treatment of patients with major depressive disorder. Wisniewski SR; Chen CC; Kim E; Kan HJ; Guo Z; Carlson BX; Tran QV; Pikalov A Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):965-72. PubMed ID: 19662630 [TBL] [Abstract][Full Text] [Related]
20. Analysis of suicidality in pooled data from 2 double-blind, placebo-controlled aripiprazole adjunctive therapy trials in major depressive disorder. Weisler RH; Khan A; Trivedi MH; Yang H; Eudicone JM; Pikalov A; Tran QV; Berman RM; Carlson BX J Clin Psychiatry; 2011 Apr; 72(4):548-55. PubMed ID: 20816039 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]